<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01748539</url>
  </required_header>
  <id_info>
    <org_study_id>4827-002</org_study_id>
    <nct_id>NCT01748539</nct_id>
  </id_info>
  <brief_title>A Phase 2 Clinical Study of KHK4827</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Parallel Group Study in Subjects With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with
      moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled,
      parallel group study. Pharmacokinetics of KHK4827 will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent improvement from baseline in Psoriasis Area and Severity Index (PASI) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PASI 75 at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI 50, 90 and 100 at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Static physician's global assessment (sPGA) of &quot;clear or almost clear (0 or 1)&quot; at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sPGA of &quot;clear (0)&quot; at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body surface area involvement (BSA) of lesion at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) 20% response (only in subjects with psoriasis arthritis)at week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and types of adverse events and adverse reactions</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of Pharmacokinetics</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Moderate to Severe Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>KHK4827 70mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KHK4827 140mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KHK4827 210mg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KHK4827</intervention_name>
    <arm_group_label>KHK4827 70mg SC</arm_group_label>
    <arm_group_label>KHK4827 140mg SC</arm_group_label>
    <arm_group_label>KHK4827 210mg SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has had stable moderate to severe plaque psoriasis for at least 6 months.

          -  Subject has received at least one previous phototherapy or systemic psoriasis therapy
             or has been a candidate to receive phototherapy or systemic psoriasis therapy in the
             opinion of the investigator.

          -  Subject has involved BSA ≥ 10% and PASI ≥ 12 at screening and at baseline.

        Exclusion Criteria:

          -  Subject diagnosed with erythrodermic psoriasis, pustular psoriasis,
             medication-induced, or medication-exacerbated psoriasis.

          -  Evidence of skin conditions at the time of the screening visit (eg, eczema) that would
             interfere with evaluations of the effect of investigational product on psoriasis.

          -  Subject has any active Common Terminology Criteria for Adverse Events (CTCAE) grade 2
             or higher infection

          -  Subject has a significant concurrent medical condition or laboratory abnormalities, as
             defined in the study protocol.

          -  Subject has used the following therapies within 14 days of the first dose: topical
             calcineurin inhibitors including tacrolimus

             , topical vitamin A, activated form D3 or activated form D3 analogue preparations,
             weak through strong topical steroids (excluding application on the scalp, axillae, and
             groin)

          -  Subject has used the following therapies within 28 days of the first dose: any other
             systemic psoriasis therapy (eg, vitamin A, calcineurin inhibitors, methotrexates,
             steroids), UVA therapy (with or without psoralen), very strong or strongest topical
             steroid, tar therapy

          -  Subject has used the following therapies within 3 months of the first dose:
             adalimumab, etanercept, infliximab, or live vaccines

          -  Subject has used ustekinumab within 6 months of the first dose

          -  Subject has previously used an anti-interleukin-17 biologic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

